Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine (Q44036716)

29 November 2017

Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine (English)

1 reference

Woodchuck hepatitis virus

29 November 2017

object named as

woodchuck hepatitis virus

1 reference

7

Raymond F Schinazi

1 reference

29 November 2017

5

John L Gerin

1 reference

29 November 2017

6

Bud C Tennant

1 reference

29 November 2017

2

Brent E Korba

1 reference

29 November 2017

Kathleen M Tatti

1

1 reference

PubMed ID

12076758

29 November 2017

Heather L Stang

series ordinal

3

1 reference

PubMed ID

12076758

29 November 2017

Simon Peek

series ordinal

4

1 reference

29 November 2017

1 July 2002

1 reference

29 November 2017

1 reference

29 November 2017

55

1 reference

29 November 2017

1

1 reference

29 November 2017

141-150

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Clinical experience with famciclovir against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Hepatocellular Carcinoma and Hepatitis B Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Sequence comparison of woodchuck hepatitis virus replicative forms shows conservation of the genome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Nucleotide sequence of a cloned woodchuck hepatitis virus genome: comparison with the hepatitis B virus sequence.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

The molecular biology of the hepatitis B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Complete nucleotide sequence of a molecular clone of woodchuck hepatitis virus that is infectious in the natural host

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Pharmacodynamics of (-)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Lamivudine therapy of WHV-infected woodchucks.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Cell-based and animal models for hepatitis B and C viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

10.1016/S0166-3542(02)00019-0

Identifiers

DOI

1 reference

29 November 2017

1 reference

PubMed ID

12076758